Paracetamol to be made in France post Covid-19


A whole production chain for paracetamol will be moved to French soil within three years, the ministries of health and the economy have announced.In a commune declaration Minister of Health Oliver Véran and junior Minister of Economy, Agnès Pannier-Runacher said that talks were underway with the French pharmaceutical companies Seqens, Upsa and Sanofi to ensure that “within three years, France will be able to produce, package and distribute paracetamol”.

Read more: France limits the sale of paracetamol due to Covid-19

Read more: New test helps verify if drugs worsen Covid-19

France to regain “independence”

This statement comes following a presidential visit to a Sanofi factory in Marcy-l’Etoile (Rhône, Auvergne-Rhône-Alpes), Tuesday June 16, during which President Emmanuel Macron indicated his wish to move more production medicine to France.

he said: “During the crisis, everyone saw that the drugs which seem banal, were not manufactured in France or in Europe. We have to draw the consequences. ”

Macron said he wanted France to gain “the independence of technology, industry and health” by producing more drugs in France.

Paracetamol is often sold in France, as the main ingredient of the painkiller Doliprane brand. At the start of foreclosure, in France, sales of Doliprane skyrocketed, as the drug is effective in treating pain and fever on both the symptoms of Covid-19.

Although the actions of medicine did not take place in France, sale had to be limited one or two packs per person during locking.

In the declaration published on June 18, Mr. Véran echoed the President’s sentiments, declaring: “no one can imagine that France would one day be unable to allow each person to have access to health care, treatment and medicine. ”

He wrote that France must focus on the recovery of “independence and autonomy through the production of essential goods”, including drugs.

The economic benefits of relocating production

The announcements made last week follow the recommendations of a government report in medicine shortages in France. The report was released in February 2020, a month before Covid-19 childbirth began in France.

In line with the report, the government wants to create an action plan to relocate industrial projects in the country, “keeping in mind their socio-economic feasibility, environmental and social external factors, and criteria of eligibility for support measured at national and European level ”.

The relocation of paracetamol production to France is a first step towards the implementation of this plan, which will also have significant economic benefits for the country, according to Ms. Pannier-Runacher.

€ 200m of investment in the development of health industries in France has been announced to accompany the plan of what, she says, “will relocate jobs and strategic structures in France”.

Related articles

France signs plan to deliver Covid vaccine by the end of 2020

Urgent appeal to catch up on vaccinations in post-Covid France

WHO stops testing for controversial hydroxychloroquine


Please enter your comment!
Please enter your name here